期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胰高血糖素样肽1及其类似物治疗2型糖尿病的研究进展 被引量：3

暂未订购
导出
摘要 糖尿病已成为继心脑血管疾病和肿瘤之后,第三位严重危害人民身体健康的慢性非传染性疾病。预计到2025年,全球糖尿病患者将达到3.66亿,其中90%为2型糖尿病（type 2 diabetes mellitus,T2DM）[1]。
作者 曾智玲
机构地区 广西桂林市中西医结合医院
出处 《内科》 2012年第2期157-159,共3页 Internal Medicine
关键词 胰高血糖素样肽1 艾塞那肽 利拉鲁肽 2型糖尿病 综述
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献23

  • 1Matthaei S,Stumvoll M,Kellerer M,et al.Pathophysiology and pharmacological treatment of insulin resistance[J].Endocr Rev,2000,21(6):585-618.
  • 2Vaidya HB,Goyal RK.Glucagon-like peptides-1 modulators as newer target for diabetes[J].Curr Drug Targerts,2008,9(10):911-920.
  • 3Fehse F,Trautmann M,Holst JJ,et al.Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes[J].J Clin Endocrinol Metab,2005,90(11):5991-7.
  • 4杨红旺,刘洋,袁勃,孟雁.GLP-1的生理作用与临床[J].中国糖尿病杂志,2009,17(1):78-80. 被引量：26
  • 5单忠艳.GLP-1类似物在糖尿病治疗中的作用[J].药品评价,2009(12):500-501. 被引量：7
  • 6Vilsboll T,Holst JJ,Knop FK.The spectrum of antidiabetic actions of GLP-1 in patients with diabetes[J].Best Pract Res Clin Endocrinol Metab,2009,23(4):453-462.
  • 7Deacon CF.Potential of liraglutide in the treatment of patients with type 2 diabetes[J].Vasc Health Risk Manag,2009,5(1):199-211.
  • 8刘瑞,胡仁明,王庆华.GLP-1类似物：糖尿病预防和治疗的新型药物[J].中国糖尿病杂志,2008,16(8):509-511. 被引量：12
  • 9King AB,Wolfe G,Healy S.Clinical observations of exenatide treatment[J].Diabetes Care,2006,29(8):1984.
  • 10Bregenholt S,Moldrup A,Blume N,et al.The long-acting glucagon-like peptide-1 analogue,liraglutide,inhibits beta-cell apoptosis in vitro[J].Biochem Biophys Res Commun,2005,330(2):577-584.

二级参考文献90

  • 1Ranganath LR. The entero-insular axis: implications for human metabolism. Clin Chem Lab Med, 2008, 46:43-56.
  • 2Drucker DJ. Glucagon like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol, 2003, 17: 161-171.
  • 3MacDonald PE, Salapatek AM, Wheeler MB. Glucagon-like peptide-1 receptor activation antagonizes voltage-dependent repolarizing K (+) currents in beta cells: a possible glucose-dependent insulinotropic mechanism. Diabetes, 2002, 51 ( Suppl 3 ): S443-S447.
  • 4Dyachok O, Isakov Y, Saqetorp J, et al. Oscillations of cyclic AMP in hormone-stimulated insulin-secreting beta-cells. Nature, 2006, 439: 349-352.
  • 5Zhou J, Egan JM. SNAP-25 is phosphorytated by glucose and GLP-1 in RIN 1046-38 cells. Bioehem Biophys Res Commun, 1997, 238: 297-300.
  • 6Klinger S, Poussin C, Debril MB, et al. Increasing GLP-1-induced beta cell proliferation by silencing the negative regulators of signaling cAMP response element modulator-alpha and DUSP14. Diabetes, 2008, 57: 584-593.
  • 7Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes, 1999, 48: 2270-2276.
  • 8Friedrichsen BN, Neubauer N, Lee YC, et al. Stimulation of pancreatic beta-cell replication by incretins involves transcriptional induction of cyclin D1 via multiple signalling pathways. J Endocrinul, 2006, 188: 481-492.
  • 9Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology, 2003, 144 5149-5158.
  • 10Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care, 2005, 28: 1083-1091.

共引文献65

同被引文献34

  • 1李光伟,Step.,L.检测人群胰岛素敏感性的一项新指数[J].中华内科杂志,1993,32(10):656-660. 被引量：2127
  • 2田爱平,郭赛珊,申竹芳.高脂饲料与胰岛素抵抗动物模型[J].中国药理学通报,2006,22(3):267-269. 被引量：52
  • 3Raun K, yon Voss P, Gotfredsen CF, et al.Liraglutide, a long-acting glucagon- like peptide-1 analog, reduces body weight and food intake in obese candy- fed rats, whereas a dipeptidyl peptidase- 1V inhibitor, vildagliptin, does not[J]. Diabetes,2007,56 ( 1 ): 8-15.
  • 4Hsu WC, Okeke E, Cheung S, et al.A cross-sectional characterization of insulin resistance by phenotype and insulin clamp in East Asian Americans with type 1 and type 2 diabetes[J].PLoS One,2011,6 ( 12 ) : 28311.
  • 5Hhaffner S, Agostino R, Mykkanen I.Insulin sensitivity in subjects with type 2 diabetes[J].Diabetes Care, 1999,22 ( 2 ) : 562-568.
  • 6Cummings BP, Stanhope KL, Graham JL, et al.Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats[J].Diabetes,2010,59 ( 10 ) 2653-2561.
  • 7HUSSAIN A, CLAUSSEN B, RAMACHANDRAN A. et al. Prevention of type 2 diabetes : A review [ J ]. Diabetes Res Clin Prac,2007,76930 (3) :317-326.
  • 8LINNEBJER G H, KOTHARE P A,PARK S, et al. Effect of renal impairment on the pharmacokinetics of exenatide [ J]. Br J Clin Pharmacol,2007,64(3) :317-327.
  • 9ROUBICEK T, MRA Z M, BARTLOVA M, et al. The influ- ence of 6-months treatment with exenatide on type 2 diabetes mellitus compensation , anthropometric and biochemical parameters [ J]. Vnitr Lek, 2010,56 ( 1 ) : 15- 20.
  • 10VILSBOLL T. Liraglutide:a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus [ J ]. Expert Opin Investig Drugs,2007,16 (2) :231-237.

引证文献3

二级引证文献17

内科
2012年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部